Bionexus (주식회사 바이오넥서스)
↗Suwon, South Korea
Bionexus is a South Korean startup founded in November 2024, specializing in AI-driven bio-data analysis solutions. The company focuses on developing an 'AI scientist' platform designed to automate fundamental research stages, such as hypothesis generation, with the goal of significantly reducing research time and costs.
Bionexus is actively involved in the South Korean government's 'K-Moonshot' initiative, which targets high-risk, high-return national missions in AI-bio. The company collaborates with domestic research institutions and technology partners, including Rebellion (AI semiconductors) and Upstage (AI foundation models), to create integrated AI products for biomedical research.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:AI-based drug discovery and bio-data analysis
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Platform company)
Modalities:AI/Digital Health
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Rebellion (AI semiconductor collaboration), Upstage (AI foundation model collaboration), Korea Basic Science Institute (Research partnership), Korea Bioengineering Research Institute (Research partnership)
COMPETITION
Position:Emerging
Competitors:Selki AI, BioResearch AI, SilicoPharm, 3BIGS
LEADERSHIP
Key Executives:
Kim Tae-hyung - CEO
LINKS
Website:bionexus.kr
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bionexus (주식회사 바이오넥서스) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bionexus (주식회사 바이오넥서스). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.